Issue link: http://osercommunicationsgroup.uberflip.com/i/365680
C h a i n D ru g s to re D a i l y 4 1 S u n d a y, Au g u s t 2 4 , 2 0 1 4 PHARMACISTS PLAY KEY ROLE IN REDESIGN OF ACTAVIS LABELS/PACKAGING Actavis generic product labels and pack- aging have received a design refresh, and pharmacists should begin seeing the changes on select products in the coming weeks. Since Watson acquired Actavis in 2012 and subsequently changed the com- bined company name to Actavis, the company has been working on a new label design to replace legacy Watson and Actavis labels. The new labels are designed to meet the needs of a wide range of users, with special consideration given to the needs of pharmacists, and in particular, how they identify, classify and differentiate between medicine packages. The new designs have been optimized, tested and reviewed by a panel of pharmacists, result- ing in an effective, easy-to- read design that promotes efficient and accurate dispensing and seeks to reduce medication errors. Some of the many features on the new Actavis packaging include: clean, simplified white labels with easy-to- read fonts; an enlarged strength bar indi- cator with unique and strategic use of color to denote separate strengths within a product family; a photograph of the actual capsule or tablet and a clearly marked quantity/dosage form indicator. Actavis, which is cur- rently distributing its generic products under both the lega- cy Watson and legacy Actavis labels, will begin a phased transition of all packaging to the new Actavis design in the coming weeks. As packaging changes are made, Actavis is committed to customer com- munications and will ensure customers are notified throughout this process. Learn more about Actavis at booth 1840 or visit www.actavis.com. MAYNE PHARMA UNVEILS NEW PACKAGING Timed with Mayne Pharma's expansion in the United States, the company has unveiled new product packaging designed to assist pharmacists and encourage patient compliance. The new packaging designs will be applied throughout the company's grow- ing portfolio of generic prescription and OTC products. This new packaging replaces and consolidates the previous packaging of Midlothian Laboratories and Libertas Pharma Inc., which were brought under the Mayne Pharma umbrella on Aug. 1. "Our new packaging will help phar- macists quickly and accurately identify products and make it easier for them to fulfill prescriptions," said Chris Schneider, Executive Vice President of Mayne Pharma's generic products. "We believe our new designs will enhance the overall pharmacy environment and sup- port greater patient safety." The new labels make use of eye- catching graphic elements and white space. Formula strengths are presented in big, bright colored ink located conve- niently between the NDC number and the drug name. The drug name appears in large, bold black print and is offset from other type. The delivery method and package size are displayed at the bottom of the label in a brightly colored block. The delivery method is displayed with both an icon and in print. The package size is highlighted with large type. "The new labels should make life easier for pharma- cists and pharmacy techni- cians by clearly reinforcing that they are pulling the right product," Schneider said. Schneider said the new product packaging was influenced by a couple of factors. "Although Mayne Pharma has a 30-year track record of innovation and success serving clients worldwide, the specialty pharmaceutical company is rel- atively new to the U.S. market," Schneider said. "Signature product pack- aging is a visible way to help incorporate subsidiary products and establish a cor- porate presence." Schneider explained that critical end-users within the phar- maceutical industry have been requesting better product packag- ing from all companies. "And Mayne Pharma was happy to comply," he said. "A key component of the Mayne Pharma corporate culture is lis- tening to our customers, understanding their needs and responding in ways that help meet those needs. The new unified look of our packaging not only demon- strates our desire to support pharmacists, it also reflects our ongoing commitment to quality and regulatory excellence." See samples of the new product packag- ing and find members of the Mayne Pharma team at booth 1924. BARBARA WALTERS TO HEADLINE 2014 NACDS FOUNDATION DINNER Known best for her exclusive interviews with world leaders, primetime specials and daytime television, renowned news correspondent, host and producer Barbara Walters will serve as the keynote speaker for the National Association of Chain Drug Stores (NACDS) Foundation Dinner, which will be held on December 3 in New York City. In its 16th year, the NACDS Foundation Dinner and contributions from the Foundation's benefactors help support evidence-based research that advances patient care, pharmacy education, student scholarships and charitable organizations that improve patient outcomes. "Throughout her career, Barbara Walters has given viewers new perspec- tives on the fascinating leaders and lumi- naries she has interviewed," said NACDS Foundation President Kathleen Jaeger. "Her ability to bring a truly per- sonal approach to the news helped her to emerge as one of the most highly- respected journalists in television history. We are deeply honored that Ms. Walters will serve as the keynote speaker for the NACDS Foundation Dinner this year." A native of Boston, Mass., Walters' television career spans more than five decades. Walters appeared on NBC's "Today Show" for 15 years. Likely most well-known for her career with the ABC network, Walters served as co-host and chief correspondent of ABC News' "20/20" for 25 years, and today is cre- ator, co-owner, executive producer and co-host of the network's "The View." Walters has received countless awards, distinctions and accolades, including Induction into the Academy of Television Arts and Sciences' Hall of Fame in 1990 "for being acknowledged worldwide as one of television's most respected interviewers and journalists;" the 2009 Daytime Emmy Award for "Outstanding Talk Show Host" for the View; and receiving a star on the Hollywood Walk of Fame. Walters is also a New York Times best-selling author for her very personal and revealing memoir "Audition," released in 2008. For more information, please visit www.nacdsfoundation.org/dinner.html. MANUFACTURER PROFILE: MALLINCKRODT Mallinckrodt Specialty Generics Mallinckrodt Pharmaceuticals started formulating and supplying industry-lead- ing pharmaceutical products more than 146 years ago. Continually building on its legacy, the company employs a verti- cally integrated process to ensure quality control during every step of the product's development from active ingredient pro- cessing through formulation, manufac- turing, and distribution. It is one of the many ways the company demonstrates its commitment to being a leader in generic pharmaceuticals. Global Leader Mallinckrodt's Specialty Generics busi- ness offers a comprehensive product portfolio with an industry-leading expertise in pain management. It is the largest U.S. supplier of opioid pain med- ications and among the top 10 generic pharmaceuticals manufacturers in the United States, based on prescriptions (source: IMS Health, Dataview, March 2012). Mallinckrodt is also one of the world's leading producers of bulk aceta- minophen. 146 Years of Tradition and Growing Mallinckrodt recently launched several new generic products to the market, con- tinuing the history of expert manufactur- ing and product development that started when the Mallinckrodt brothers formed the first chemical manufacturing compa- ny west of the Mississippi. The Specialty Generics business developed as a natural extension of the company's acetaminophen raw materials business. Many of the generic products use the sifted acetaminophen produced by Mallinckrodt's Active Pharmaceutical Ingredients (API) business, which allows the company to ensure a reliable source and quality of supply. Mallinckrodt saw potential in the generics business and decided to pursue manufacturing its own tablets. In 1996, the company purchased Graham Labs in Hobart, New York, to add specialty generics to its portfolio of businesses. Investing in the Future The same goal of providing high-quality, innovative products that began 146 years ago with the Mallinckrodt brothers con- tinues today. "Our company believes in the origi- nal values that built Mallinckrodt so many years ago – quality, service and integrity," said Mark Trudeau, President and Chief Executive Officer, Mallinckrodt Pharmaceuticals. "Recently launched as a standalone company, we're building on our tradition by investing in our core strengths of manufacturing and development. We're committed to meet- ing customer needs for today while also creating a long-term growth strategy that will continue our ability to meet patient needs for generations to come." Mallinckrodt's Specialty Generics business is investing in several infra- structure and capacity improvements to consistently deliver the high-quality products customers need. Expansion of the high-volume manufacturing facility in Hobart will increase production of generic pharmaceuticals, and new packaging lines will improve product output. Investments also are being made within Mallinckrodt's API busi- ness to increase capacity and reliability of raw materials for generic pharma- ceuticals. These investments through- out the Mallinckrodt specialty pharma- ceuticals business will ensure that a quality product is available to cus- tomers for years to come. For more information, visit booth 315, call 800-325-8888 or go to www.mallinckrodt.com.